Shingles and Chickenpox (Varicella-Zoster Virus)

Posted by john on June 28th, 2006 — in Ultram News

Postherpetic neuralgia is difficult to treat. Once PHN develops, a multidisciplinary approach that involves a pain specialist, psychiatrist, primary care physician, and other health-care providers may provide the best means to relieve the pain and distress associated with this condition. At this time, some experts recommend the following treatment steps:
First, topical preparations, usually the lidocaine […]

Shingles and Chickenpox (Varicella-Zoster Virus)

Posted by john on June 26th, 2006 — in Ultram News

Treatment for Postherpetic Neuralgia
Postherpetic neuralgia is difficult to treat. Once PHN develops, a multidisciplinary approach that involves a pain specialist, psychiatrist, primary care physician, and other health-care providers may provide the best means to relieve the pain and distress associated with this condition. At this time, some experts recommend the following treatment steps:
[…]

Fibromyalgia Symptoms Respond to Acupuncture

Posted by john on June 20th, 2006 — in Ultram News

ROCHESTER, Minn., June 16 — Acupuncture not only offered pain relief for fibromyalgia patients, but it significantly improved fatigue and anxiety symptoms, Mayo Clinic researchers reported.
This prospective, partially blinded, controlled, randomized trial included 50 fibromyalgia patients who had met American College of Rheumatology criteria for the disorder and had tried conservative treatments, including dietary […]

Drug mix can cause severe side effects

Posted by john on June 14th, 2006 — in Ultram News

Q. My doctor prescribed tramadol with APAP for headaches. He also wrote prescriptions for Lexapro and Effexor for depression and anxiety. He said that Effexor and Lexapro are both antidepressants, but they work on different parts of the brain. When I went to fill the new Lexapro and refill the tramadol prescription, the pharmacist would […]

Combining Mainstream, Alternative Therapies Brings Back Pain Relief

Posted by john on June 11th, 2006 — in Ultram News

THURSDAY, May 25 (HealthDay News) — Used together, conventional and complementary/alternative treatments help patients ease their low back pain better than using mainstream treatment alone, U.S. research shows.
The small study included 13 patients who received “integrated” care and six patients who received usual care. The integrative care team at Brigham and Women’s Hospital in Boston […]

Ask the Clinician: Answers to Readers’ Questions

Posted by john on June 8th, 2006 — in Ultram News

Dr. Krusz is a recognized expert in the fields of headache and Migraine treatment and pain treatment. To read more about Dr. Krusz, click HERE.
Please note: We cannot handle emergencies or diagnose via the Internet. Please do not ask us to diagnose; see your physician for diagnosis.
If you have a question for this section […]

Biovail Faces Generic Competition

Posted by john on June 5th, 2006 — in Ultram News

Biovail reported first-quarter results largely in-line with analyst and company expectations, with earnings of 43 cents per share and a 27% increase in total revenues to $220.5 million, from $175.3 million last year.
Revenues from strong sales of its lead product, Wellbutrin XL, helped Biovail (nyse: BVF - news - people ) meet or beat street […]

Biovail 1st-Qtr Profit Rises Sixfold on Wellbutrin (Update3)

Posted by john on June 3rd, 2006 — in Ultram News

May 11 (Bloomberg) — Biovail Corp., Canada’s largest publicly traded drugmaker, said first-quarter profit climbed almost sixfold as labor costs declined and sales of the antidepressant Wellbutrin XL increased.
Net income rose to $64.5 million, or 40 cents a share, from $11.1 million, or 7 cents, a year earlier, Mississauga, Ontario- based Biovail said today […]

Biovail Reports First-Quarter 2006 Financial Results; Company Records Total Revenues of $220.5 Million; Operating Margins of 35.1%; EPS From Continuing Operations of $0.43; Cash Flow From Operations of $94.7 Million

Posted by john on June 2nd, 2006 — in Ultram News

Biovail Corporation (NYSE:BVF)(TSX:BVF) today announced financial results for the three-month period ending March 31, 2006. To the extent that this news release contains forward-looking statements, investors are cautioned that these are based on our current views, and actual outcomes are not certain. For more information, see the note on forward-looking information following the conference call […]